China Animal Husbandry Industry Co Ltd (CAHIC), a subsidiary of China National Agricultural Development Group Corp, is a manufacturer and service provider specializing in animal health and nutrition products. The company’s business portfolio includes the production and sales of animal health products and animal nutrition products. Its products include major animal disease vaccines, multivitamin additives, laying hen premixes, and tylosin. It also offers veterinary biological products such as poultry vaccines, livestock vaccines, and pet vaccines.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CAHIC's R&D arm focuses on on animal health and nutrition products. The company is involved in developing vaccines for major animal diseases, diagnostic products, and therapeutic bacteriophage products. It also focuses on new technologies for veterinary drug formulation, specialized drugs for aquatic animals, and novel disinfectant products. Additionally, CAHIC is working on feed research, including protein source development and enzyme and bacteria functional packages. The R&D unit of CAHIC is responsible for managing the company's research and development activities. This unit oversees the application, review, and approval procedures for open research projects, ensuring that projects align with the company's strategic goals and comply with funding and intellectual property requirements. In FY2024, the company spent CNY143.89 million on R&D, which as a percentage of revenue stood at 2.4%, and grew 17.1% YoY.